TG Therapeutics, Inc. (TGTX)
TGTX Stock Price Chart
Key Info
| Market Cap | 3.72B |
| Revenue (ttm) | 152,000 |
| Net Income (ttm) | -230.74M |
| Shares Out | 119.18M |
| EPS (ttm) | -2.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $28.28 |
| Previous Close | $27.78 |
| Change ($) | 0.50 |
| Change (%) | 1.80% |
| Day's Open | 27.92 |
| Day's Range | 27.10 - 28.28 |
| Day's Volume | 801,696 |
| 52-Week Range | 7.12 - 31.10 |
TGTX Stock News
NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company's investigation...
Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET
Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and anal...
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company develop...
UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR= 0 .54, p
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the com...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Compan...
TG Therapeutics (NASDAQ: TGTX) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients w...
NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Applica...
TG Therapeutics (TGTX) CEO, Michael Weiss on Q2 2020 Results - Earnings Call Transcript
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developme...
Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbrali...
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced...
Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET Presentation scheduled for Thursday, June 18, 2020, at 3:40 PM ET
NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25th European Hematology Association (EHA) annual congress includi...
The development-stage company appears to be on the path to commercial operations.
Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET
The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapy
With the worst of the coronavirus priced into markets, the U.S. economy is slowly reopening, serving as another boon for small-cap stocks.
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), ...
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG...
By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology...
NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Con...
$40 million of which came from longtime shareholder, RA Capital Management $40 million of which came from longtime shareholder, RA Capital Management
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ublituximab was generally well tolerated across all cohorts including those patients receiving one-hour infusions for the 450mg dose currently being studied in the Phase 3 ULTIMATE MS program
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company’s Board of Directors. Dr. Lonial ...
Today, we update the investment thesis on two oncology concerns whose stocks have been on fire here in April despite the continued COVID-19 outbreak.
TG Therapeutics: 2020 Offers Investors A Cascade Of Clinical And Regulatory Catalysts
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to umbralis...
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2019 Results - Earnings Call Transcript
Acceleron Pharma, Novavax, and TG Therapeutics are all on the cusp of hitting major milestones.
These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.
TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.
Two triple-combination therapies delivered impressive results in early-stage studies, which propelled the stock to a 170% gain in 2019.
Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.
TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Company anticipates ending 2019 with approximately $140 million in cash, providing funding well into 2021 Company anticipates ending 2019 with approximately $140 million in cash, providing fun...
With two pivotal data readouts and potentially three NDA filings coming in the next twelve months, it is time to revisit TG Therapeutics.
About TGTX
TG Therapeutics, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic... [Read more...]
| Industry Biotechnology | IPO Date Dec 14, 1995 |
| CEO Michael Weiss | Employees 217 |
| Stock Exchange NASDAQ | Ticker Symbol TGTX |
Financial Performance
In 2019, TGTX's revenue was $152,000, a change of 0.00% compared to the previous year's $152,000. Losses were -$172.87 million, -0.35% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is 47.43, which is an increase of 67.72% from the latest price.